Dr. Jonathan A. Webster, M.D.
Medical Oncology (Medical Oncology Physician)
601 N Caroline St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Stanford University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 124
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Stanford University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D78073
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 565
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 169 | 28 |
| Established patient office or other outpatient visit, 40-54 minutes | 119 | 42 |
| Bone marrow, smear interpretation | 65 | 64 |
| Established patient office or other outpatient visit, 30-39 minutes | 56 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 14 |
| Hospital discharge day management, more than 30 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sprycel (dasatinib) | 43 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Baltimore, MD | 35 |
| Venclexta (venetoclax) | 33 |
| Tibsovo (ivosidenib) | 29 |
| Posaconazole | 21 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Baltimore, MD | 14 |
| Amlodipine Besylate Other prescribers in Baltimore, MD | 13 |
| Niacin Er (niacin) Other prescribers in Baltimore, MD | 11 |
| Methotrexate (methotrexate sodium) Other prescribers in Baltimore, MD | 11 |
| Calcitriol Other prescribers in Baltimore, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 17 payments worth $7,192 in total to this clinician.
| Rigel Pharmaceuticals, Inc. | $3,746 |
|---|---|
| Autolus Inc | $3,338 |
| Viiv Healthcare Company | $64.43 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Honoraria | $5,860 |
|---|---|
| Travel and Lodging | $799 |
| Food and Beverage | $490 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $3,120 |
| Rigel Pharmaceuticals, Inc. Sep 19, 2025 | Honoraria Rezlidhia · Acute Myeloid Leukemia | $2,740 |
| Rigel Pharmaceuticals, Inc. Sep 2, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX · in-kind | $302 |
| Rigel Pharmaceuticals, Inc. Sep 2, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX · in-kind | $259 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX | $60.00 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX | $58.50 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX | $52.93 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX | $47.08 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Rigel Pharmaceuticals, Inc. Sep 30, 2025 | Travel and Lodging Rezlidhia · Acute Myeloid Leukemia · travel to Houston, TX | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $2,885,215 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Prec…
Amgen Inc. - Calaspargase pegol in adults with all
Servier Bioinnovation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.